Marta Moreno Torres.
Marta Moreno Torres. A Universitat de València (UV) and IIS La Fe team, integrated in the Biomedical Research Centre in Network of Hepatic and Digestive Diseases (CIBERehd), has proven the potential of metabolomics for the study of hepatotoxicity of new medical drugs thanks to its relevance as a discovery tool of new biomarkers. Marta Moreno Torres, a Ramón y Cajal fellowship researcher of the Universitat de València, is the main author of the study. The hepatotoxicity, or Drug-Induced Liver Disease (DILI), is one of the most frequent adverse clinical reactions and an important cause of morbidity and mortality. It is one of the main causes of drug recalls, both in the early stages of development and during clinical usage, once it is already approved. This is why this issue constitutes a crucial concern for the pharmaceutical industry, with sanitary and economic repercussions. The research team has studied different aspect of medical drugs' hepatotoxicity with the aim of identifying DILI biomarkers based on metabolomics.
